The Library
The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition
Tools
Tools
Tools
Wall, Mark J., Wigmore, Geoffery, Lopatář, Ján, Frenguelli, Bruno G. and Dale, Nicholas (2008) The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition. Neuropharmacology, Vol.55 (No.7). pp. 1251-1258. doi:10.1016/j.neuropharm.2008.08.005
Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1016/j.neuropharm.2008.08.005
Abstract
Understanding the mechanisms and properties of purinergic signalling would be greatly assisted by the discovery of subtype selective and potent inhibitors of the NTPDase enzymes, which metabolise nucleotides such as ATP and ADP in the extracellular space. Currently ARL 67156 is the best available NTPDase inhibitor, but its relatively poor efficacy means that negative results are difficult to interpret. POM-1 (sodium polyoxotungstate) is a novel NTPDase inhibitor, which has shown promising results with the inhibition of recombinant NTPDases 1, 2 and 3. We have tested the effectiveness and physiological effects of POM-1 with cerebellar and hippocampal slices. Using the malachite green phosphate assay, HPLC and biosensor measurements we have found that POM-1 is more effective at blocking ATP breakdown in cerebellar slices than ARL 67156. The site of inhibition is at the first step of the breakdown cascade (conversion of ATP to ADP) and the effects of POM-1 appear readily reversible. However, POM-1 has multiple effects on synaptic transmission. At the cerebellar parallel fibre-Purkinje cell (PF) synapse POM-1 produced a long lasting inhibition of transmission, which was preceded in a minority of synapses by a transient increase in PF excitatory postsynaptic potential (EPSP) amplitude (similar to 20%). This increase in PF EPSP amplitude appears to result from a reduction in the tonic activation of presynaptic A, receptors, consistent with POM-1 preventing the breakdown of ATP to adenosine. The reduction in PF EPSP amplitude does not however appear to result from NTPDase inhibition as it persists when both adenosine and ATP (P2Y and P2X) receptors are blocked. An increase in paired pulse ratio and a reduction in presynaptic volley amplitude suggest that there is a presynaptic component of POM-1 action which reduces glutamate release. POM-1 produced similar inhibition at climbing fibre synapses and at hippocampal CA1 pyramidal synapses. Thus although POM-1 is more effective than ARL 67156 at blocking ATP breakdown its usefulness is limited by off-target actions on synaptic transmission. (C) 2008 Elsevier Ltd. All rights reserved.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | Q Science > QP Physiology R Medicine > RS Pharmacy and materia medica |
||||
| Divisions: | Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- ) | ||||
| Library of Congress Subject Headings (LCSH): | Enzyme inhibitors, Adenosine triphosphatase, Neural transmission, Cerebellum, Hippocampus (Brain), Biosensors | ||||
| Journal or Publication Title: | Neuropharmacology | ||||
| Publisher: | Pergamon | ||||
| ISSN: | 0028-3908 | ||||
| Official Date: | December 2008 | ||||
| Dates: |
|
||||
| Volume: | Vol.55 | ||||
| Number: | No.7 | ||||
| Number of Pages: | 8 | ||||
| Page Range: | pp. 1251-1258 | ||||
| DOI: | 10.1016/j.neuropharm.2008.08.005 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access | ||||
| Funder: | Epilepsy Research UK |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
